The global Sjogren's syndrome market is predicted to develop as a result of an expanding and strong medication pipeline. For instance, according to information published in July 2022 on the Nation Institute of Medicine (NIH), a multicenter phase 3 study is currently underway to evaluate the effectiveness and safety of the drug ianalumab in patients with Sjogren's syndrome. The study's anticipated completion date is March 2026. Throughout the course of the projection period, the market for drugs to treat sjogren's syndrome is anticipated to rise significantly due to increased research and development.
The global Sjogren’s Syndrome Market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).
Leading Companies in the Sjogren’s syndrome Industry:
Daiichi Sankyo Co Ltd
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. On May 2020, it was reported that GSK tap experimental arthritis antibody to calm cytokine storm hitting COVID-19 patients.